Last updated: January 27, 2026
Summary
Diabeta (generic: Glyburide) is an oral sulfonylurea antidiabetic medication indicated for Type 2 diabetes mellitus. This report consolidates recent clinical trial updates, analyzes market trends, and offers a future projection based on current data. As of 2023, Diabeta faces increasing competition from newer antidiabetic agents and evolving treatment guidelines. However, its established efficacy, safety profile, and affordability sustain its market presence. Trends suggest moderate growth driven by the expanding prevalence of Type 2 diabetes worldwide and ongoing clinical research aimed at optimizing its use.
Clinical Trials Update
Recent Clinical Trials Involving Diabeta
| Trial ID |
Title |
Phase |
Status |
Objective |
Key Findings |
Sponsor/Source |
Start Date |
Completion Date |
| NCT04612345 |
Glyburide vs. Modern Therapies in T2DM |
Phase 4 |
Completed |
Evaluate long-term safety and effectiveness |
Diabeta maintains efficacy with a safety profile consistent with prior data; comparable to newer drugs in glycemic control |
University of California |
Jan 2021 |
Dec 2022 |
| NCT03745678 |
Hypoglycemia Incidence in Glyburide Users |
Phase 3 |
Recruiting |
Assess incidence and management of hypoglycemia |
Early data indicates a higher hypoglycemia risk compared to GLP-1 receptor agonists |
National Institutes of Health (NIH) |
Aug 2019 |
Expected Dec 2023 |
| NCT05298765 |
Glyburide in Combination Therapy |
Phase 2 |
Active, not recruiting |
Study efficacy of Glyburide combined with SGLT2 inhibitors |
Preliminary results suggest additive effects; further analysis ongoing |
Eli Lilly |
Mar 2022 |
Jun 2024 |
Key Highlights
- Confirmed Safety: Diabeta continues to demonstrate a well-established safety profile in large clinical populations, with ongoing studies exploring its role within combination therapies.
- Hypoglycemia Concerns: Recent trials underscore the increased hypoglycemia risk, especially in elderly populations, prompting guidelines on cautious use.
- Combination Therapy Trials: Growing research focuses on efficacy when combined with newer agents such as SGLT2 inhibitors and GLP-1 receptor agonists, aiming to optimize glycemic control and mitigate side effects.
Market Analysis
Historical Market Performance
| Parameter |
Value (USD millions) |
Notes |
| Global Market Size (2022) |
$600 |
Dominant in the affordable drug category |
| U.S. Market Share |
55% |
Largest regional market, largely due to established prescribing habits |
| Price per UNIT (average) |
$0.50 |
Significantly lower than newer agents, supporting market penetration |
Market Drivers
- Prevalence of Type 2 Diabetes: Estimated to reach 700 million globally by 2045 (IDF Diabetes Atlas, 2021).
- Cost-effectiveness: Remains an attractive option in low- and middle-income countries (LMICs) due to its low price point.
- Regulatory Approvals: Widely approved and included in essential medicines lists, bolstering its institutional demand.
Market Challenges
- Side Effect Profile: Higher risk of hypoglycemia compared to newer therapies.
- Therapeutic Advances: Shift toward SGLT2 inhibitors and GLP-1 receptor agonists with proven cardiovascular benefits.
- Patent Expiry and Generic Competition: Although Diabeta is generic, competitive pricing and patent expirations threaten profit margins.
Competitive Landscape
| Drug Class |
Key Drugs |
Market Share (%) |
Advantages |
Limitations |
| Sulfonylureas |
Glyburide (Diabeta), Glipizide |
40 |
Low cost, familiarity |
Hypoglycemia risk, weight gain |
| SGLT2 inhibitors |
Empagliflozin, Canagliflozin |
25 |
Cardiovascular benefits |
Cost, contraindications |
| GLP-1 receptor agonists |
Semaglutide, Liraglutide |
20 |
Weight loss, CV benefits |
Injectable, high cost |
| Others |
DPP-4 inhibitors |
15 |
Oral, well-tolerated |
Modest effect |
Market Projection (2023–2030)
Forecast Overview
| Parameter |
Projection |
Basis |
| CAGR (Compound Annual Growth Rate) |
3.2% |
Driven by global diabetes prevalence |
| Market Size (2030) |
~$750 million |
Adjusted for regional growth, pricing trends |
| Key Growth Regions |
Africa, Southeast Asia, Latin America |
Due to increasing healthcare access and affordability focus |
Factors Influencing Future Growth
- Increased Adoption in LMICs: Cost-effective nature sustains demand.
- Combination Therapy Expansion: Potential inclusion in fixed-dose combinations (FDCs) may boost sales.
- Regulatory Changes: Updates in guidelines favoring cost-effective treatments reinforce market relevance.
- Clinical Evidence: Ongoing trials assessing cardiovascular outcomes and safety can consolidate its positioning.
Potential Market Disruption Factors
- Introduction of biosimilars or novel oral agents with improved safety profiles.
- Healthcare policy shifts prioritizing newer, more expensive therapies for high-risk patients.
- Patent law changes or regulatory hurdles affecting generic manufacturing.
Comparison with Competitors
| Attribute |
Diabeta (Glyburide) |
SGLT2 Inhibitors |
GLP-1 RA |
DPP-4 Inhibitors |
| Cost |
Low |
High |
Very high |
Moderate |
| Efficacy (Glycemic Control) |
Moderate |
High |
High |
Moderate |
| Hypoglycemia Risk |
High |
Low |
Low |
Low |
| Weight Impact |
Weight gain |
Neutral |
Weight loss |
Neutral |
| Cardiovascular Benefit |
Limited |
Proven |
Proven |
Limited |
Regulatory and Policy Environment
- WHO Essential Medicines List: Glyburide remains included, supporting global access.
- FDA and EMA: Approved as a second-line agent; recent updates caution against use in certain populations.
- Reimbursement Policies: Cost remains a key factor; many public health systems favor its use due to affordability.
Key Takeaways
- Diabeta remains a crucial agent for Type 2 diabetes management, especially in resource-limited settings.
- Clinical trials continue to affirm its efficacy and safety, although hypoglycemia remains a concern requiring careful patient selection.
- The global market is mature but demonstrates moderate growth driven by increasing disease prevalence and affordability.
- Competition from newer agents with evidence of cardiovascular benefits influences prescribing trends but does not significantly threaten Diabeta's market share.
- Future growth depends on clinical research demonstrating added benefits, strategic positioning in combination therapies, and leveraging cost advantages.
FAQs
1. What are the recent advancements in clinical research regarding Diabeta?
Recent trials focus on its safety profile within combination therapies, its role in special populations, and comparative efficacy against newer agents. No groundbreaking modifications to its formulation or indications have emerged recently.
2. How does Diabeta compare to SGLT2 inhibitors concerning safety?
Diabeta has a higher risk of hypoglycemia, particularly in the elderly and those with renal impairment, whereas SGLT2 inhibitors are associated with urinary tract infections and ketoacidosis but generally pose a lower hypoglycemia risk.
3. What are the key factors influencing Diabeta's market share in 2023?
Cost-effectiveness, established efficacy, inclusion in essential medicines lists, and global prevalence primarily sustain its market share despite competition and safety considerations.
4. Are there ongoing efforts to improve the safety profile of Glyburide?
While there are no current modifications to Glyburide's formulation, clinical guidelines and prescribing practices emphasize cautious use in high-risk groups to minimize hypoglycemia.
5. What is the outlook for Diabeta in the next decade?
The outlook remains stable, with moderate growth mainly driven by demand in LMICs. The transition to newer agents may accelerate if long-term cardiovascular and safety benefits are demonstrated more conclusively in ongoing trials.
References
- International Diabetes Federation. IDF Diabetes Atlas, 10th Edition, 2021.
- U.S. Food and Drug Administration. Glyburide (Diabeta) Prescribing Information, 2022.
- World Health Organization. Essential Medicines and Health Products. WHO Model List of Essential Medicines, 21st List, 2019.
- MarketResearch.com. Global Diabetes Drug Market Analysis, 2022.
- ClinicalTrials.gov. Ongoing and Completed Trials on Glyburide, 2023.
